Innovative Antibody-Drug Conjugates to address Resilient Malignancies
NanoTherix is a preclinical biotech company pioneering innovative antibody-drug conjugates (ADCs) to tackle refractory malignancies, one of the most critical unmet needs in oncology and often unaddressed by conventional ADCs.
NanoTherix pioneers groundbreaking Nanobody-Drug Conjugates (NDCs) targeting novel resistance-associated antigens for glioblastoma and other cancers. The NDCs are engineered as either bispecific or monospecific agents and are designed to eliminate tumor cells, including those resistant to existing therapies. The NDCs employ groundbreaking tumor antigens and tumor type optimized payloads to maintain efficacy and counteract resistance mechanisms.